Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Growth 2023-2029

Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Growth 2023-2029

23-Valent Pneumococcal Polysaccharide Vaccine is a kind of vaccine used to prevent infection caused by pneumococcal bacteria. 23-Valent Pneumococcal Polysaccharide Vaccine contains 23 of the most common types of pneumococcal bacteria. 23-Valent Pneumococcal Polysaccharide Vaccine is for use only in adults and children who are at least 2 years old. For children younger than 2 years old, another vaccine called Prevnar (pneumococcal conjugate vaccine [PCV] 7-valent) is used, usually given between the ages of 2 months and 15 months.
LPI (LP Information)' newest research report, the “23-Valent Pneumococcal Polysaccharide Vaccine Industry Forecast” looks at past sales and reviews total world 23-Valent Pneumococcal Polysaccharide Vaccine sales in 2022, providing a comprehensive analysis by region and market sector of projected 23-Valent Pneumococcal Polysaccharide Vaccine sales for 2023 through 2029. With 23-Valent Pneumococcal Polysaccharide Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world 23-Valent Pneumococcal Polysaccharide Vaccine industry.
This Insight Report provides a comprehensive analysis of the global 23-Valent Pneumococcal Polysaccharide Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on 23-Valent Pneumococcal Polysaccharide Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global 23-Valent Pneumococcal Polysaccharide Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for 23-Valent Pneumococcal Polysaccharide Vaccine and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global 23-Valent Pneumococcal Polysaccharide Vaccine.
The global 23-Valent Pneumococcal Polysaccharide Vaccine market size is projected to grow from US$ 1114.7 million in 2022 to US$ 2265.8 million in 2029; it is expected to grow at a CAGR of 2265.8 from 2023 to 2029.
Merck is the largest manufacturers of 23-Valent pneumococcal polysaccharide vaccine in the world, has a share about 78%. Other players include Sinovac, Kangtai Bio, CDIBP, Walvax, etc. United States is dominating the global 23-Valent pneumococcal polysaccharide vaccine market, has a share nearly 78% in terms of production. The largest market is United States, holds a share about 48%, followed by China and Europe, with around 25% and 22% market share respectively.
This report presents a comprehensive overview, market shares, and growth opportunities of 23-Valent Pneumococcal Polysaccharide Vaccine market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Single Dose Vial
Pre-filled Syringe
Segmentation by application
For Children (Over 2 Years Old)
For Adult
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Merck
Sinovac
Kangtai Bio
CDIBP
Walvax
Key Questions Addressed in this Report
What is the 10-year outlook for the global 23-Valent Pneumococcal Polysaccharide Vaccine market?
What factors are driving 23-Valent Pneumococcal Polysaccharide Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do 23-Valent Pneumococcal Polysaccharide Vaccine market opportunities vary by end market size?
How does 23-Valent Pneumococcal Polysaccharide Vaccine break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.